COMPANY
Clinical Phase 2
Profile checked Oct 10, 2026
Keywords: Non-small Cell Lung Cancer Cutaneous Melanoma Melanoma Head and Neck Squamous Cell Carcinoma Leiomyosarcoma Liposarcoma OR502 OR2805
Timeline
- Trial start Phase 1/Phase 2: A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents source ↗
- Trial start Phase 1/Phase 2: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Phase 1/Phase 2 | Recruiting | Oct 24, 2023 | Aug 1, 2026 (estimated) |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | Phase 1/Phase 2 | Unknown status (ClinicalTrials.gov) | Sep 9, 2021 | Apr 15, 2024 (estimated) |
